

Cell Therapy Human Raw Materials Market Expected to Surge to USD 18.1 Billion by 2032 at a CAGR of 22.6%

Innovative advancements and increasing adoption of cell-based treatments drive exponential growth in the Cell Therapy Human Raw Materials Market

AUSTIN, TX, UNITED STATES, November 25, 2024 /EINPresswire.com/ -- The Global [Cell Therapy Human Raw Materials Market](#) was valued at USD 2.9 billion in 2023 and is projected to reach USD 18.1 billion by 2032, growing at a robust CAGR of 22.6% during the forecast period of 2024-2032.



Cell Therapy Human Raw Materials Market Overview

The Cell Therapy Human Raw Materials Market is pivotal for regenerative medicine and biopharmaceutical innovation. It focuses on acquiring blood products, tissue samples, and culture media that are quintessential for the production of cell therapies. Increasing the use of cell-based therapies for chronic illnesses, cancer, autoimmune diseases, and genetic disorders drives the market. The success of therapies such as CAR-T and stem cell treatments significantly depends on the quality and consistency of these raw materials. Leukapheresis products must be precise for CAR-T therapies to ensure cell viability, whereas stem cell treatments depend on contaminated culture media and growth factors for the optimization of therapeutic outcomes. Severe regulatory standards, even FDA validation processes, are necessary to ensure that these materials remain contamination-free and effective. As clinical trials and research continue to expand, the demand for reliable, high-quality materials will remain critical in advancing regenerative medicine.

Get a Free Sample Report of Cell Therapy Human Raw Materials Market @ <https://www.snsinsider.com/sample-request/4487>

Key Cell Therapy Human Raw Materials Market Players:

Thermo Fisher Scientific Inc.
Lonza Group AG
Miltenyi Biotec GmbH
Stemcell Technologies Inc.
Bio-Techne Corporation
BD Biosciences
GE Healthcare Life Sciences
Macopharma
NantCell Inc.
CellGenix GmbH
Other key players

Segment analysis

By Product

In 2023, the Cell Culture Media segment dominated the Cell Therapy Human Raw Materials Market, capturing approximately 40% of the market share. Cell culture media is a crucial ingredient necessary to support the growth or upkeep of cells in a controlled environment. Good cell culture media are necessary for the success of any application in cell therapy, as they help with cell growth, differentiation, and function. For example, unique media formulations, such as those designed for stem cell treatments or CAR-T cell treatments, must be developed carefully to address the specific needs of various cell types and ensure optimal therapeutic results. The growing desire for cutting-edge cell therapies and the need for tailored media solutions to meet various therapeutic needs leads to a significant market presence in this sector.

By End-Use

In 2023, Biotechnology & Pharmaceutical Companies was the dominating segment in the Cell Therapy Human Raw Materials Market, with an estimated market share of 55%. Because of significant investments and emphasis put forth by these companies in the advancement and promotion of cell-based therapies, the need for large quantities of top-notch raw materials is essential in this situation. The leading biotech firms developing cutting-edge therapies like gene editing and regenerative medicine depend on highly specialized raw materials to guarantee effectiveness and safety. Biotechnology & Pharmaceutical Companies play a significant role in advancing modern cell culture media, growth factors, and other necessary components by dedicating substantial resources to research, clinical trials, and production methods. Its dominant market position results from extensive production and innovation efforts in this field.

Need any customization research on Cell Therapy Human Raw Materials Market, Enquire Now @ <https://www.snsinsider.com/enquiry/4487>

Key Market Segments

By Product

Cell Culture Media
Cell Culture Sera
Cell Culture Supplements (Proteins, Growth Factors, Nucleotides, Others)
Reagents & Buffers
Others

By End-Use
Biotechnology & Pharmaceutical Companies
CROs & CMOs
Academic & Research Institutions
Hospitals & Clinics

Regional analysis

In 2023, North America was the dominating region in the cell therapy human raw materials market, with a 47% market share. The advantageous government regulations, along with a rising need for unique new treatments and heightened involvement from key companies in creating cell-based therapies for various chronic illnesses. Furthermore, a significant amount of prominent companies in the area are engaged in manufacturing and marketing cell-based products. This is expected to boost the need for human raw materials in cell therapy, leading to growth in the segment. Additionally, the partnerships between leading industry players and smaller biotech firms increase competition as companies strive to secure their top spots in the rapidly expanding cell therapy market. In January 2023, Kite, a Gilead subsidiary, entered into a strategic partnership with Arcellx, Inc. to work on developing and selling CART-ddBCMA for relapsed multiple myeloma.

Recent Developments

In October 2024, BD Biosciences introduced a new line of GMP-compliant reagents aimed at simplifying cell therapy manufacturing procedures. These products aim to improve the survival and performance of cells, tackling important issues in quality and adherence to regulations. In September 2024, Lonza Group revealed plans to greatly increase its cell therapy manufacturing facilities by integrating advanced technologies in order to increase production capacity and address the increasing global need for top-notch raw materials.

Buy Full Research Report on Cell Therapy Human Raw Materials Market 2024-2032 @
<https://www.snsinsider.com/checkout/4487>

Table of Contents – Major Key Points

1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)

1.3 Research Assumptions

2. Executive Summary

2.1 Market Overview

2.2 Regional Synopsis

2.3 Competitive Summary

3. Research Methodology

3.1 Top-Down Approach

3.2 Bottom-up Approach

3.3. Data Validation

3.4 Primary Interviews

4. Market Dynamics Impact Analysis

4.1 Market Driving Factors Analysis

4.1.2 Drivers

4.1.2 Restraints

4.1.3 Opportunities

4.1.4 Challenges

4.2 PESTLE Analysis

4.3 Porter's Five Forces Model

5. Statistical Insights and Trends Reporting

5.1 Regulatory Compliance (2023)

5.2 Research-Driven Innovation, (2023), by Region

5.3 Healthcare Spending, by region, (Government, Commercial, Private, Out-of-Pocket), 2023

6. Competitive Landscape

7. Cell Therapy Human Raw Materials Market by Product

8. Cell Therapy Human Raw Materials Market by End Use

9. Regional Analysis

10. Company Profiles

11. Use Cases and Best Practices

12. Conclusion

Speak with Our Expert Analyst Today to Gain Deeper Insights @

<https://www.snsinsider.com/request-analyst/4487>

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence,

we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Akash Anand

SNS Insider Pvt. Ltd

415-230-0044

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/763572505>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.